Patents by Inventor Jeffrey Millman

Jeffrey Millman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230392124
    Abstract: Among the various aspects of the present disclosure is the provision of methods and compositions for the generation of cells of endodermal lineage and beta cells and uses thereof.
    Type: Application
    Filed: April 16, 2021
    Publication date: December 7, 2023
    Applicant: Washington University
    Inventors: Jeffrey Millman, Kristina Maxwell, Nathaniel Hogrebe, Leonardo Velazco-Cruz, Daniel Veronese Paniagua
  • Publication number: 20230340417
    Abstract: Among the various aspects of the present disclosure is the provision of methods and compositions for the generation of cells of endodermal lineage and beta cells and uses thereof.
    Type: Application
    Filed: April 20, 2023
    Publication date: October 26, 2023
    Inventors: Nathaniel Hogrebe, Jeffrey Millman
  • Publication number: 20230014430
    Abstract: Among the various aspects of the present disclosure is the provision of methods and compositions for the generation of functionally mature beta cells having enhanced SIX2+ activity and therapeutic benefit and uses thereof. An aspect of the present disclosure provides for a method of generating SIX2-enhanced SC-? cells. In some embodiments, the method comprises providing a population of SC-? cells (or EP cells); providing a SIX2 positive regulator; and/or incubating the population of SC-? cells and the SIX2 positive regulator.
    Type: Application
    Filed: November 20, 2020
    Publication date: January 19, 2023
    Applicant: Washington University
    Inventors: Jeffrey Millman, Daniel Veronese Paniagua, Kristina Wernes, Leonardo Velazco-Cruz
  • Publication number: 20220403340
    Abstract: Among the various aspects of the present disclosure is the provision of a media for cryopreserved cells and methods of making and using same. An aspect of the present disclosure provides for a cell media formulation comprising (e.g., for day 0) one or more components selected from: MCDB 131; Glutamax; P/S; BSA; Glucose; ZnSO4; an enzyme for digesting DNA (e.g., DNASE1); and/or an apoptosis inhibitor (e.g., BI-6C9).
    Type: Application
    Filed: June 13, 2022
    Publication date: December 22, 2022
    Inventors: Jeffrey Millman, Leonardo Velazco-Cruz, Punn Augsornworawat
  • Patent number: 10597639
    Abstract: Disclosed herein is a 3D-printed, biocompatible macroporous device that houses stem cell derived ?-cell (SC-? cell) clusters within a degradable fibrin gel. Cluster sizes are used that avoid severe hypoxia within 3D-printed devices and a microwell-based technique is used for resizing clusters within this range. 3D-printed devices may function for at least 12 weeks, are retrievable, and maintain structural integrity.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: March 24, 2020
    Assignee: Washington University
    Inventors: Jeffrey Millman, Jiwon Song
  • Publication number: 20180119106
    Abstract: Disclosed herein is a 3D-printed, biocompatible macroporous device that houses stem cell derived ?-cell (SC-? cell) clusters within a degradable fibrin gel. Cluster sizes are used that avoid severe hypoxia within 3D-printed devices and a microwell-based technique is used for resizing clusters within this range. 3D-printed devices may function for at least 12 weeks, are retrievable, and maintain structural integrity.
    Type: Application
    Filed: October 20, 2017
    Publication date: May 3, 2018
    Applicant: Washington University
    Inventors: Jeffrey Millman, Jiwon Song